(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Don’t let food poisoning crash your Thanksgiving dinner - 2She just became the first wheelchair user to travel to space
- 3Cyclone causes blackout, flight chaos in Brazil's Sao Paulo
- 4Yemen’s Aden airport shut by STC-backed transport minister, Saudi source says
- 5Tatiana Schlossberg, JFK's granddaughter, dies at 35 after terminal cancer diagnosis
- Careful Connections: Building Association and Trust
- This Canadian crater looks like marbled meat | Space photo of the day for Jan. 6, 2026
- NASA astronauts take new moonsuit for a swim | Space photo of the day for Nov. 28, 2025
- Nutrient Rich Natural products: Lift Your Wellbeing
- Like many holiday traditions, lighting candles and fireplaces is best done in moderation
- Vote In favor of Your Favored Menial helper Administration
- Scientists document a death from a meat allergy tied to certain ticks
- Vote In favor of Your Favored Web-based Venture Stage
- Figure out How to Score Huge with Open Record Rewards
